T he use of drug-eluting stent (DES) is favored in real-world clinical practice because it reduces the rates of restenosis and subsequent target lesion revascularization (TLR) compared with bare-metal stents. [1] [2] [3] However, the widespread use of DES has raised long-term safety concerns. In particular, first generation DES can be associated with risks of late TLR and stent thrombosis (ST) beyond 1 year after treatment. 4 Stent fracture (SF) after DES implantation has become a critical issue because it is a predisposing factor of in-stent restenosis, TLR, and ST. The incidence of SF after implantation of sirolimus-eluting stent (SES), one of the first generation DES, has been reported to range from 0.84% to 7.7%. [5] [6] [7] SES is also more likely to cause SF because of its platform, closed-cell design, relatively thicker stent strut, and stainless steel with low flexibility and conformability. 8 Several studies showed that SF after DES implantation was associated with higher rates of adverse cardiac events in the first year [9] [10] [11] [12] ; however, it remains unclear whether SF increases the risk of adverse cardiac events in the long term, especially beyond 5 years after DES implantation. The aim of this study was to assess whether SF was related to adverse cardiac events in 8-year clinical outcomes, including the rates of death, myocardial infarction, very late ST (VLST), and TLR. Impact of Sirolimus-Eluting Stent Fracture (ticlopidine, 200 mg/d or clopidogrel, 75 mg/d) were prescribed to all patients, and they were advised to continue double antiplatelet therapy (DAPT) for at least 8 months after stent implantation. Among them, 972 patients (85.1%) with 1795 lesions underwent follow-up angiography within 1 year after the initial procedure. We excluded 147 lesions with any TLR and 18 lesions lost to follow-up because of the death or ST of the patients within 1 year on a per-lesion basis. We also excluded 18 patients who died or in whom ST developed on a per-patient basis. The patients with any TLR within 1 year after SES implantation were not excluded from long-term follow-up on a per-patient basis. The final assessment of this retrospective singlecenter study encompassed 954 patients with 1630 lesions. The study flow chart in Figure I in the Data Supplement describes how the study sample was selected. The study was done in accordance with the provisions of the Declaration of Helsinki and the guidelines for epidemiological studies issued by the Ministry of Health, Labor, and Welfare of Japan. Informed consent was provided for both the procedure and subsequent data collection and analysis for research purposes, and the study was approved by the Institutional Ethics Committee.
Angiographic Analysis
According to our institutional protocol, follow-up coronary angiography is scheduled 8 months after PCI. In patients whose initial target lesions were chronic total occlusions or in whom left main stenting was performed, follow-up angiography is added at 3 months after PCI. Some patients in this study sample underwent multiple angiographies within 1 year after DES implantation. For the lesions with documented SF, the first follow-up angiography that documented SF was regarded as the index coronary angiographic study for the assessment of long-term clinical outcomes.
A quantitative coronary angiographic analysis was conducted by the technicians at Kurashiki Central Hospital using QCA-CMS (Medis Medical Imaging Systems, Leiden, The Netherlands). Angiographic measurements were obtained from multiple projections after intracoronary nitrate injection. A lesion was defined as the location covered by a single stent or multiple overlapping stents. Reference diameter, minimum lumen diameter, and percent diameter stenosis were measured before and after PCI.
SF was defined as the complete separation of stent segments or stent struts confirmed by follow-up angiography and evaluated through multiple projections. 13 To assess the interobserver variability, the angiographic diagnosis of SF required an independent view and the agreement of 2 independent cardiologists (M.O. and K.K.) who were blinded to the clinical and procedural data. Furthermore, 1 of the 2 observers (M.O.) evaluated all the angiograms again after the initial evaluation to assess the intraobserver variability for the diagnosis of SF. In case of disagreement, the evaluation of a third observer (T.T.) was obtained and the final decision on the diagnosis of SF was made by consensus.
Clinical End Points
The primary end point was defined as any TLR. On a per-patient basis, the clinical end points were defined as all-cause death, cardiac death, myocardial infarction, and definite VLST. Other clinical outcomes, such as any TLR and clinically driven TLR, were evaluated on a per-lesion basis. Clinical outcomes were collected either from hospital charts
WHAT IS KNOWN
• Stent fracture after sirolimus-eluting stent implantation is associated with target lesion revascularization and stent thrombosis at 1 year.
• Whether stent fracture increases the risk of late adverse cardiac events is unknown.
WHAT THE STUDY ADDS
• Stent fracture is associated with target lesion revascularization both between 1 and 5 years and beyond 5 years.
• Stent fracture is associated with very late stent thrombosis during an 8-year follow-up. Data are expressed as numbers (%) unless otherwise indicated. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention; and SF, stent fracture.
or by contacting patients, their family members, or referring physicians, and evaluated at 8 years. Myocardial infarction was defined as ischemic symptoms or ischemic change of ECG plus elevation of creatine kinase levels to twice the upper limit of normal, with a rise in creatine kinase-MB fraction. Definite VLST was defined as angiographically or pathologically confirmed ST beyond 1 year after SES implantation, according to the Academic Research Consortium definition. 14 TLR was defined as either repeated PCI or coronary bypass grafting for restenosis or thrombosis of the target lesion that included the proximal and distal edge segments in coronary angiography. Clinically driven TLR was defined as TLR for typical chest pain or showing objective evidence of ischemia (either electrocardiographic change during a spontaneous episode of pain or abnormal results on exercise electrocardiography, stress nuclear perfusion scan, or pressure-wire assessment).
Statistical Analysis
Data were presented as mean±SD for continuous variables. Numbers and percentages were reported for categorical variables. Continuous variables were compared with the unpaired Student t test or the Mann-Whitney U test, depending on the distribution. Categorical variables were compared between groups with using the χ 2 test or the Fisher exact test.
The cumulative incidences of clinical events were estimated by the Kaplan-Meier method, and the differences between groups were assessed by the log-rank test. To evaluate the late TLR events beyond 5 years, a landmark analysis at 5 years was conducted. The lesions with the individual end point events before 5 years were excluded from the landmark analysis. Cox proportional hazards regression analysis was performed to adjust the primary end point for confounders. P<0.05 was considered statistically significant. The inter-and intraobserver variability in diagnosis of SF was evaluated using Cohen κ coefficient. Data were analyzed using the IBM SPSS statistical software (version 20, IBM Corp, Armonk, NY). The differences in the baseline patient characteristics between non-SF and SF groups are shown in Table 1 . The rate of men in the SF group was significantly lower than in the non-SF group. Beside sex, no other patient characteristics were significantly different between the 2 groups. The baseline lesion and procedural characteristics of the non-SF and SF groups are shown in Table 2 . The SF group had significantly greater lesion complexity compared with the non-SF group. In addition, the incidence of SF in the right coronary artery was significantly higher and the vessel diameter in the SF group was significantly greater than in the non-SF group.
Results
The cumulative incidences of clinical events at 8 years are shown in Table 3 . In this study sample, the cumulative rate of any TLR was significantly higher in the SF group (38.1% versus 10.8%, P<0.001; Figure 1A) . The cumulative rate of clinically driven TLR was also significantly higher in the SF group (26.2% versus 6.6%, P<0.001; Figure 1B) . In a landmark analysis, both the cumulative rates of any TLR from 1 to 5 years and beyond 5 years were significantly higher in the SF group (25.1% versus 8.2%, P<0.001 and 17.4% versus 2.9%, P<0.001; Figure 1C ). The cumulative rates of clinically driven TLR from 1 to 5 years and beyond 5 years were also significantly higher in the SF group (18.7% versus 4.4%, P<0.001 and 9.2% versus 2.3%, P=0.01; Figure 1D ). A representative case of very late TLR in the SF group is shown in Figure 2 .
After adjusting for statistically different factors (with P≤0.10: sex, left main trunk disease, culprit for the right coronary artery, long lesion [lesion length >30 mm], small vessel diameter [reference diameter <2.75 mm], chronic total occlusion, in-stent restenosis, ostial lesion, angulated lesion, calcified lesion, and SF lesion), the association between SF and any TLR at 8 years remained significant (hazard ratio, 1.33; 95% confidence interval, 1.02-1.77; P=0.03).
The cumulative rates of all-cause death and cardiac death at 8 years did not differ between the SF and non-SF groups (23.5% versus 27.6%, P=0.34 and 4.7% versus 9.1%, P=0.14). However, the cumulative rates of myocardial infarction and definite VLST were significantly higher in the SF group (10.1% versus 3.3%, P=0.001 and 6.8% versus 0.7%, P<0.001; Figure 3) .
The characteristics of patients with VLST are shown in Table I in the Data Supplement. The modes of DAPT cessation were based on the PARIS registry. 15 VLST occurred in 6 patients in the SF group. Among them, 4 patients took 1 antiplatelet drug (4 discontinuations) and 2 patients did not take any of antiplatelet drugs (a disruption and a brief interruption). 
Discussion
The main findings of this study are as follows: (1) the cumulative rates of any TLR and clinically driven TLR between 1 and 8 years were significantly higher in the SF group after SES implantation; (2) those beyond 5 years were also significantly higher in the SF group; and (3) the cumulative rate of definite VLST for 8 years was significantly higher in the SF group. To the best of our knowledge, this study represents the first report of long-term clinical outcomes of SF after SES implantation beyond 5 years. Whether SF after SES implantation without early clinical events is related to the long-term clinical events is a controversial issue. Umeda et al 16 reported that although patients with angiographically detected partial or complete SF after SES implantation had higher rates of major adverse cardiac events at 4 years compared with those without SF, the increases in the event rates between 1 and 4 years were not significantly different between the 2 groups. However, it was reported that complete SF after SES implantation detected with angiography and intravascular ultrasound was a strong predictor of late instent restenosis and that complete SF after SES implantation detected with multislice computed tomography without early clinical events was associated with late TLR events. 17, 18 In this study, the cumulative rate of each TLR in the SF group also appeared to be considerably high and consistently increasing. The difference in the SF definition, or the degree of SF severity, could explain the discrepancy in these findings. In addition, the characteristics of this study, such as larger number of patients, longer follow-up period, and higher follow-up rate, seem to better reflect the real-world clinical experience.
The exact mechanisms by which SF after SES implantation causes VLST are unknown, although several VLST cases clinically associated with SF after SES implantation have been reported. 19, 20 It is speculated that in SF lesions, various factors underlying the development of VLST, such as inflammatory reaction, lack of complete endothelialization of stent struts, and hypersensitivity reaction of the coronary artery, are promoted beyond 1 year. [21] [22] [23] It is uncertain whether these study findings can be applied to various kinds of DES implantations, however, there are a huge number of patients with a history of SES implantation. The results of this study seem to indicate that patients with SF lesions after SES implantation require more careful follow-up.
DAPT for 6 months after DES implantation is recommended in the current European Society of Cardiology guidelines. 24 Although, extended DAPT beyond 6 months in patients at high ischemic risk and low bleeding risk is provided with a class II-b recommendation, 24 patients who benefit from longer DAPT are not specified yet, whose optimal duration of DAPT is not determined. In this study, no patients in the SF group had been continuing DAPT when VLST occurred. It can be concluded that the continuation of DAPT in patients with SF is recommended as long as possible when their bleeding risk is low because the ischemic problems associated with SF never go away.
Study Limitations
Several limitations of this study should be considered. First, this was a retrospective and observational study. Second, the follow-up coronary angiography was not performed in all patients after SES implantation; nevertheless, the rate of follow-up coronary angiography in this study was relatively high. Third, DAPT extension in each patient was not considered and bleeding complications were not evaluated. Finally, whether SF after other types of DES implantation yields similar results is unknown.
Conclusions
SF after SES implantation was consistently associated with higher rates of adverse cardiac events during the 8-year follow-up.
